Oncology portfolio edges Chugai to first-half growth
This article was originally published in Scrip
Executive Summary
Solid sales of anticancer products helped drive growth at Roche's Japanese subsidiary Chugai in the first half ended 30 June, although the figures were held back by the general April price revision in Japan and falls for older products.